P0DTC1 (R1A_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Replicase polyprotein 1a UniProtKBInterProInteractive Modelling
4405 aa; Sequence (Fasta) ;
2 identical sequences: Severe acute respiratory syndrome coronavirus 2: A0A6G7KRG6, A0A6G6A224
It is possible new templates exist for this target since these models were created.
Available Structures
Host translation inhibitor nsp1 1-180; PRO_0000449635
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 5E11 refined against a… | monomer | 100.0 | 1×NT9; | |||
Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 11C6 refined against a… | monomer | 100 | 1×OF6; | |||
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7k7p.1.A | monomer | 0.76 | 100.00 | |||
6zoj.1.8 | monomer | 0.67 | 100.00 | |||
Non-structural protein 2 181-818; PRO_0000449636
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7msw.1.A | monomer | 0.84 | 3×ZN; | 100.00 | ||
Papain-like protease nsp3 819-2763; PRO_0000449637
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
Structure of the SARS-COV2 PLpro (C111S) in complex with a dimeric Ubv that inhibits activity by an… |
Heteromer P62987; | 100 | 1×ZN; 2×BR; | |||
Crystal structure of the SARS-CoV-2 papain-like protease (PLPro) C112S mutant | homo-2-mer | 99.68 | 2×ZN; 2×PO4; | |||
Structure of SARS-CoV-2 Papain-like protease PLpro in complex with 3, 4-Dihydroxybenzoic acid, meth… | homo-2-mer | 100 | 2×HE9; 4×GOL; 2×ZN; 8×PO4; 2×CL; | |||
SARS-CoV-2 PLpro in complex with inhibitor WEHI-P24 | homo-2-mer | 99.66 | 2×A1A0V; 2×ACY; 2×GOL; | |||
Structure of SARS-CoV-2 NSP3 macrodomain in the apo form | homo-2-mer | 100 | 2×CL; 2×MPO; | |||
SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-89 | monomer | 100 | 1×ZN; 2×SO4; 1×XT7; 1×GOL; | |||
SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-83 | monomer | 100 | 1×ZN; 4×SO4; 2×BO3; 1×Y54; | |||
SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-24 | monomer | 100 | 1×XR8; 1×ZN; 2×SO4; 3×BO3; | |||
Crystal structures of SARS-CoV-2 papain-like protease in complex with covalent inhibitors | monomer | 100 | 1×A1D7X; 1×ZN; | |||
SARS-CoV-2 papain-like protease (PLpro) bound to PF-07957472 | monomer | 99.68 | 1×A1AZ1; 1×TFA; 1×ZN; | |||
SARS CoV-2 PLpro in complex with inhibitor 3k | monomer | 99.67 | 1×S88; 4×ZN; 1×DMS; | |||
SARS-CoV-2 PLpro in complex with inhibitor WEHI-P4 | monomer | 99.68 | 1×A1A0U; 2×ZN; 1×CL; | |||
SARS-CoV-2 PLpro in complex with inhibitor WEHI-P1 | monomer | 99.66 | 1×A1A0T; 1×SIN; | |||
SARS-CoV-2 PLpro in complex with inhibitor WEHI-P2 | monomer | 99.66 | 1×A1A0S; 1×ACY; 3×GOL; | |||
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
6ywk.3.A | monomer | 0.84 | 100.00 | |||
6w9c.1.A | monomer | 0.80 | 1×ZN; | 100.00 | ||
3e9s.1.A | monomer | 0.79 | 1×TTT; 1×ZN; | 82.86 | ||
7cmd.4.A | monomer | 0.79 | 1×TTT; 1×ZN; | 100.00 | ||
2w2g.1.A | monomer | 0.79 | 75.00 | |||
6wuu.2.A | monomer | 0.79 | 1×ACE; 1×ZN; | 99.69 | ||
2kqv.1.A | monomer | 0.75 | 78.13 | |||
2kqw.1.A | monomer | 0.71 | 80.22 | |||
2k87.1.A | monomer | 0.69 | 81.74 | |||
Non-structural protein 4 2764-3263; PRO_0000449638
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
Crystal Structure of the C-terminal Cytoplasmic Domain of nsp4 from SARS-CoV-2 | homo-6-mer | 100 | 8×NA; | |||
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
3vcb.1.A | homo-2-mer | 0.72 | 61.36 | |||
3C-like proteinase nsp5 3264-3569; PRO_0000449639
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
SARS-CoV-2 Mpro Double Mutant (H41A and T21I) in complex with nsp4/5 peptidyl substrate |
Heteromer P0DTD1; | 99.34 | ||||
Structure of compound 1 bound to SARS-CoV-2 main protease | homo-2-mer | 100.0 | 2×A1IVK; 4×EDO; 3×BR; 1×NA; | |||
Structure of compound 119 bound to SARS-CoV-2 main protease | homo-2-mer | 100 | 2×A1ITI; 1×CL; 1×NA; | |||
Structure of compound 1 bound to SARS-CoV-2 main protease | homo-2-mer | 100 | 2×A1ITJ; 1×DMS; 1×CL; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGD; 1×PG4; 3×BR; 1×NA; 1×CL; | |||
SARS-CoV-2 3CL protease with a bound inhibitor | homo-2-mer | 100 | 2×A1JGF; 4×DMS; 3×EDO; 1×CL; 1×NA; 1×SO4; | |||
CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE COMPLEXED WITH FRAGMENT F01 | homo-2-mer | 100 | 4×NA; 4×DMS; 2×5P9; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGP; 2×DMS; 1×NA; 1×CL; | |||
SARS-CoV-2 main protease with a bound inhibitor | homo-2-mer | 100 | 2×A1JGE; 2×DMS; 3×NA; 1×CL; | |||
SARS-CoV-2 Mpro (Omicron, P132H+T169S) in complex with alpha-ketoamide 13b-K | homo-2-mer | 99.35 | 2×O6K; | |||
Crystal structure of SARS-CoV-2 Mpro in complex with cyclic peptide GM4 including unnatural amino a… | homo-2-mer | 100 | 2×PEG; 1×DMS; 2×EDO; 1×PGE; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGO; 1×NA; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGG; 2×DMS; 1×NA; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGK; 2×DMS; 2×SO4; 3×NA; | |||
SARS-CoV-2 Main protease bound to a non-covalent non-peptidic HTS hit | homo-2-mer | 100 | 4×DMS; 3×EDO; 1×SO4; 2×A1A21; 2×A1AFD; 1×GOL; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 1×A1JGH; 1×SO4; 1×NA; 1×DMS; | |||
SARS-CoV-2 Mpro (Omicron, P132H+T169S) free enzyme | homo-2-mer | 99.35 | ||||
Crystal structure of SARS-CoV-2 Mpro Mutant P132H | homo-2-mer | 99.67 | ||||
Crystal structure of SARS-CoV-2 Mpro with compound 12 | homo-2-mer | 100 | 2×A1IL7; 7×SO4; 5×GOL; 2×EDO; | |||
SARS-CoV2 Main Protease (Mpro) in complex with the covalent inhibitor 28a | homo-2-mer | 100 | 2×A1IYL; | |||
Structure of SARS-CoV-2 Mpro in complex with its degrader | homo-2-mer | 100 | 2×A1LYZ; | |||
Crystal structure of SARS-CoV-2 Mpro with AB-343. | homo-2-mer | 100 | 2×A1IMY; 1×CL; 2×PEG; 2×EDO; | |||
Crystal Structure of SARS-CoV-2 Main Protease (Mpro) T21I Mutant | homo-2-mer | 99.67 | ||||
Crystal structure of the Mpro of SARS COV-2 in complex with the MG-87 inhibitor | homo-2-mer | 100 | 2×MXU; 1×CL; | |||
Crystal Structure of SARS-CoV-2 Main Protease (Mpro) L50F/E166A/L167F Triple Mutant | homo-2-mer | 99.02 | ||||
Crystal structure of SARS-CoV-2 Main Protease (Mpro) with covalent inhibitor 5,8-Dihydroxy-1,4-naph… | homo-2-mer | 100.0 | 2×PEG; 1×X7F; 1×DMS; | |||
Crystal structure of SARS-CoV-2 Mpro Mutant P132H with C5a | homo-2-mer | 99.67 | 2×WZK; | |||
Structure of 3CL protease with a bound inhibitor | homo-2-mer | 100 | 2×A1JF8; 1×DMS; 1×NA; | |||
Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the noncovalently bound inhibi… | homo-2-mer | 100 | 4×DMS; 1×A1IHT; 1×CL; 1×MG; | |||
Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the noncovalently bound inhibi… | homo-2-mer | 100 | 4×DMS; 1×A1IHV; 1×IMD; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGN; | |||
SARS-CoV-2 Mpro in complex with a silicon-containing inhibitor | homo-2-mer | 100 | 1×GOL; 2×A1IRW; 14×SO4; 9×CL; 1×DMS; | |||
Crystal Structure of T21I SARS-CoV-2 Main Protease in Complex with Nirmatrelvir | homo-2-mer | 99.67 | 2×4WI; | |||
SARS-CoV-2 Mpro (Omicron,P132H) in complex with alpha-ketoamide 13b-K at pH 8.5 | homo-2-mer | 99.67 | 2×O6K; 1×CL; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGB; 2×SO4; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGV; 2×SO4; 1×NA; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGM; 2×DMS; 1×NA; | |||
Crystal structure of SARS-CoV-2 3CL protease (3CLpro) in complex with compound 44 | homo-2-mer | 100 | 2×A1D50; | |||
SARS-COV2 Main Protease in complex with inhibitor MG-131 | homo-2-mer | 100 | 2×I8H; 2×NA; | |||
SARS-CoV-2 Mpro in Complex with RK-107 | homo-2-mer | 100 | 2×A1IMU; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGT; | |||
Crystal structure of SARS-CoV-2 Mpro with compound 5 | homo-2-mer | 100 | 2×A1IL0; | |||
Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with X77 | homo-2-mer | 99.67 | 2×X77; | |||
Crystal Structure of T21I SARS-CoV-2 Main Protease | homo-2-mer | 99.67 | ||||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGS; 1×NA; | |||
Crystal Structure of T21I SARS-CoV-2 Main Protease in Complex with Compound Mpro61 | homo-2-mer | 99.67 | 1×XEK; | |||
Crystal structure of the SARS-CoV-2 main protease in complex with SY110 | homo-2-mer | 99.67 | 2×LVX; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGI; 1×SO4; 1×NA; | |||
Structure of 3CL protease with a bound inhibitor | homo-2-mer | 100 | 2×A1JF7; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGC; 1×NA; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100 | 2×A1JGU; | |||
Crystal structure of SARS-Cov-2 main protease E166N mutant in complex with Bofutrelvir | homo-2-mer | 99.34 | 2×FHR; | |||
Crystal structure of SARS-CoV-2 3CL protease (3CLpro) in complex with compound 51 | homo-2-mer | 100 | 2×A1D51; | |||
SARS-CoV-2 with a bound inhibitor | homo-2-mer | 100.0 | 2×A1JGR; | |||
SARS-CoV-2 3CL protease (3CL pro) in complex with a novel inhibitor | homo-2-mer | 100 | 2×A1D70; | |||
SARS-COV2 Main Protease in complex with inhibitor MG78 | homo-2-mer | 100 | 2×I70; 2×CL; 4×NA; | |||
SARS-CoV-2 Mpro in complex with compound 12d inhibitor | homo-2-mer | 100 | 2×GLY; 2×VAL; 2×THR; 2×PHE; 2×A1ALW; | |||
Crystal structure of the SARS-CoV-2 main protease in complex with Hit-1 | homo-2-mer | 100.0 | 2×LV0; 4×DMS; | |||
Crystal structure of SARS-Cov-2 main protease in complex with X77 | homo-2-mer | 100 | 2×X77; | |||
Crystal structure of SARS-CoV-2 main protease in complex with C5 | homo-2-mer | 99.67 | 2×A1LX2; | |||
Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with X77 | homo-2-mer | 99.67 | 2×X77; | |||
Crystal structure of SARS-CoV-2 main protease in complex with C2 | homo-2-mer | 99.67 | 2×A1LX1; | |||
Crystal structure of SARS-CoV-2 main protease in complex with TMP1 | homo-2-mer | 100 | ||||
Crystal Structure of T21I SARS-CoV-2 Main Protease in Complex with GC376 | homo-2-mer | 99.67 | 2×UED; | |||
Crystal structure of SARS-Cov-2 main protease, pH=6.5 | homo-2-mer | 100 | ||||
Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with X77 | homo-2-mer | 99.67 | 2×X77; | |||
Crystal structure of SARS-Cov-2 main protease in complex with S217622 | homo-2-mer | 100 | 2×7YY; | |||
Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with X77 | homo-2-mer | 99.66 | 2×X77; | |||
Crystal structure of SARS-CoV-2 3CL protease in complex with compound 4 | homo-2-mer | 100.0 | 2×A1L7Q; | |||
Crystal structure of SARS-Cov-2 main protease D48N mutant in complex with PF07321332 | homo-2-mer | 99.66 | 2×4WI; | |||
Crystal structure of SARS-Cov-2 main protease, pH=6.0 | homo-2-mer | 100.0 | ||||
Crystal structure of SARS-Cov-2 main protease, pH=8.5 | homo-2-mer | 100.0 | ||||
Crystal structure of SARS-Cov-2 main protease D48N mutant in complex with shikonin | homo-2-mer | 99.32 | 1×FNO; | |||
Crystal structure of SARS main protease in complex with PF-00835231 | homo-2-mer | 96.19 | 2×V2M; | |||
Crystal structure of SARS-Cov-2 main protease D48N mutant | homo-2-mer | 99.66 | ||||
SARS-CoV-2 3CLpro bound to covalent inhibitor | monomer | 100 | 1×XQF; | |||
Crystal structure of SARS-CoV-2 main protease in complex with Mp-4D7 | monomer | 100.0 | ||||
Crystal structure of SARS-CoV-2 main protease in complex with Mp-4L2 | monomer | 100 | ||||
Crystal structure of SARS-CoV-2 3CL protease in complex with compound 17 (S-892216) | monomer | 100 | 1×A1L7R; | |||
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
5rfv.1.B | homo-2-mer | 0.91 | 2×T8J; | 100.00 | ||
5r7z.1.B | homo-2-mer | 0.91 | 2×HWH; | 100.00 | ||
2z9j.1.A | homo-2-mer | 0.89 | 2×DTZ; | 96.08 | ||
6lu7.1.B | homo-2-mer | 0.89 | 100.00 | |||
6y2g.1.A | homo-2-mer | 0.88 | 1×GLY; 2×O6K; | 100.00 | ||
2a5i.1.B | homo-2-mer | 0.87 | 2×AZP; | 96.08 | ||
Non-structural protein 7 3860-3942; PRO_0000449641
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
SARS-CoV-2 E-RTC complex with RNA-nsp9 and GMPPNP |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GNP; 1×MG; | |||
A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GTP; | |||
SARS-CoV-2 E-RTC complex with SMP-nsp9 and GTP |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GTP; 1×6GS; | |||
SARS-CoV-2 E-RTC bound to pRNA-nsp9 and GDP-BeF3- |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GDP; 1×BEF; 1×MG; | |||
SARS-CoV-2 RNA E-RTC complex with RMP-nsp9 and GMPPNP |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GNP; 1×MG; 1×F86; | |||
SARS-CoV-2 core polymerase complex inhibited by araCTP |
Heteromer P0DTD1; | 100 | 2×ZN; 2×MG; 2×HF4; | |||
Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mecha… |
Heteromer P0DTD1; | 100 | 13×ZN; 1×MG; | |||
SARS-CoV-2 E-RTC complex with RNA-nsp9 |
Heteromer P0DTD1; | 100 | 8×ZN; 2×MN; | |||
A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 100 | 8×ZN; 2×MN; 1×U5P; | |||
SARS-CoV-2 E-RTC bound with MMP-nsp9 and GMPPNP |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GNP; 1×6GS; | |||
A mechanism for SARS-CoV-2 RNA capping and its inhibitor of AT-527 |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GNP; | |||
A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GNP; 1×U5P; | |||
SARS-CoV-2 C-RTC with 13-TP |
Heteromer P0DTD1; | 100 | 2×ZN; 2×MG; | |||
SARS-CoV-2 E-RTC complex with SMP-nsp9 and GMPPNP |
Heteromer P0DTD1; | 100 | 8×ZN; 1×GNP; 1×MG; 1×6GS; | |||
SARS-CoV-2 Replication-Transcription Complex has a dimer-of-dimeric architecture (ddRTC) in pre-cap… |
Heteromer P0DTD1; | 100 | 32×ZN; 2×ADP; 2×MG; 1×PO4; | |||
Structure of SARS-CoV-2 RNA-dependent RNA polymerase with gossypol binding |
Heteromer P0DTD1; | 100 | 2×GO3; | |||
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
6m71.1.B | monomer | 0.80 | 100.00 | |||
7jlt.1.A | monomer | 0.79 | 100.00 | |||
2ahm.1.B | monomer | 0.75 | 98.80 | |||
Non-structural protein 8 3943-4140; PRO_0000449642
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
2ahm.1.H | monomer | 0.77 | 97.47 | |||
7jlt.1.D | monomer | 0.76 | 100.00 | |||
6nur.1.B | monomer | 0.76 | 97.47 | |||
2ahm.1.E | monomer | 0.70 | 97.47 | |||
6m71.1.D | monomer | 0.70 | 100.00 | |||
RNA-capping enzyme subunit nsp9 4141-4253; PRO_0000449643
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
1qz8.1.A | homo-2-mer | 0.79 | 97.35 | |||
6w4b.1.A | homo-2-mer | 0.79 | 100.00 | |||
1uw7.1.B | homo-2-mer | 0.73 | 97.35 | |||
Non-structural protein 10 4254-4392; PRO_0000449644
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00258 |
Heteromer P0DTD1; | 100 | 1×MI7; 1×DMS; 4×ZN; | |||
Ensemble model of ligand-free SARS-CoV-2 NSP10-NSP14 (ExoN) and in complex with partially bound VT0… |
Heteromer P0DTD1; | 100 | 1×A1IGP; 4×ZN; 2×DMS; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00180 |
Heteromer P0DTD1; | 100 | 2×DMS; 1×A1IGR; 4×ZN; 2×MG; | |||
Ensemble model of ligand-free SARS-CoV-2 NSP10-NSP14 (ExoN) and in complex with partially bound VT0… |
Heteromer P0DTD1; | 100 | 1×VSL; 1×DMS; 4×ZN; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00219 |
Heteromer P0DTD1; | 100 | 4×ZN; 2×MG; 1×A1IGN; 1×DMS; | |||
Ensemble model of ligand-free SARS-CoV-2 NSP10-NSP14 (ExoN) and in complex with partially bound VT0… |
Heteromer P0DTD1; | 100 | 1×DMS; 4×ZN; 1×A1IGO; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00249 |
Heteromer P0DTD1; | 100 | 4×ZN; 1×A1IGL; 1×MG; | |||
Ensemble model of ligand-free SARS-CoV-2 NSP10-NSP14 (ExoN) and in complex with partially bound VT0… |
Heteromer P0DTD1; | 100 | 4×ZN; 1×MG; 1×UYY; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00421 |
Heteromer P0DTD1; | 100 | 1×A1IGI; 4×ZN; 1×DMS; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00216 |
Heteromer P0DTD1; | 100 | 4×ZN; 1×A1IGM; 1×MG; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00218 |
Heteromer P0DTD1; | 100 | 4×ZN; 2×A1IGJ; 1×MG; | |||
Crystal Structure of SARS-CoV-2 NSP10-ExoN in complex with VT00019 |
Heteromer P0DTD1; | 100 | 4×ZN; 1×A1IGQ; | |||
Crystal Structure of SARS-CoV-2 NSP10-NSP14 (ExoN) in complex with VT00198 |
Heteromer P0DTD1; | 100 | 4×ZN; 1×A1IGK; 1×MG; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 1 |
Heteromer P0DTD1; | 100 | 1×MES; 1×MTA; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 11 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H4D; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 5 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H28; 2×GOL; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 7 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H3D; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 6 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H3A; 2×GOL; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 4 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H3E; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 8 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H29; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 10 |
Heteromer P0DTD1; | 100 | 1×A1H4B; 1×MES; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 9 |
Heteromer P0DTD1; | 100 | 1×A1H4C; 1×MES; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H3B; 3×GOL; 2×ZN; | |||
SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2 |
Heteromer P0DTD1; | 100 | 1×MES; 1×A1H3C; 2×ZN; | |||
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
2g9t.1.A | homo-12-mer | 0.80 | 24×ZN; | 97.12 | ||
6w4h.1.B | monomer | 0.77 | 2×ZN; | 100.00 | ||